Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study)

Abstract

PURPOSE: (1) To improve survival rates in patients with Ewing's sarcoma (ES) or peripheral neuroectodermal tumours (PNET) using semi-continuous chemotherapy and aiming to perform surgery in all; (2) To identify early prognostic factors to tailor therapy for future studies. PATIENTS AND METHODS: One hundred and forty-one patients were entered onto the trial between January 1988 and December 1991. Induction therapy consisted of five courses of Cytoxan, 150 mg/m(2) x 7 days, followed by Doxorubicin, 35 mg/m(2) i.v on day 8 given at short intervals. Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological response to CT. Maintenance chemotherapy consisted of vincristine + actinomycin and cytoxan + doxorubicin. The total duration of therapy was 10 months. RESULTS: After a median follow-up of 8.5 years, the projected overall survival at 5 years was 66% and disease-free survival (DFS) was 58%. In patients treated by surgery, only the histological response to CT had an influence on survival: 75% DFS for patients with a good histological response (less than 5% of cells), 48% for intermediate responders and only 20% for poor responders (> or = 30% of cells), P < 0.0001. The initial tumor volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact on DFS in patients treated by radiation therapy alone. Age had no impact on outcome. CONCLUSION: Therapeutic trials for localized Ewing's sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local therapy.

References 25

1. 1.

   Arai Y., Kun L. E., Brooks M. T., Fairclough D. L., Fontanesi J., Meyer W. H., Hayes F. A., Thompson E., Rao B. N. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21(6):1501-1508.

   Not in our library10.1016/0360-3016(91)90325-x (opens in a new tab)

2. 2.

   Bacci G., Ferrari S., Bertoni F., Rimondini S., Longhi A., Bacchini P., Forni C., Manfrini M., Donati D., Picci P. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000;18(1):4-11.

   Not in our library10.1200/jco.2000.18.1.4 (opens in a new tab)

3. 3.

   Bacci G., Ferrari S., Comandone A., Zanone A., Ruggieri P., Longhi A., Bertoni F., Forni C., Versari M., Rimondini S. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol. 2000;39(1):111-116.

   Not in our library10.1080/028418600431076 (opens in a new tab)

4. 4.

   Bacci G., Picci P., Gherlinzoni F., Capanna R., Calderoni P., Putti C., Mancini A., Campanacci M. Localized Ewing's sarcoma of bone: ten years' experience at the Istituto Ortopedico Rizzoli in 124 cases treated with multimodal therapy. Eur J Cancer Clin Oncol. 1985;21(2):163-173.

   Not in our library10.1016/0277-5379(85)90168-3 (opens in a new tab)

5. 5.

   Barbieri E., Emiliani E., Zini G., Mancini A., Toni A., Frezza G., Neri S., Putti C., Babini L. Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys. 1990;19(5):1165-1170.

   Not in our library10.1016/0360-3016(90)90223-7 (opens in a new tab)

6. 6.

   Craft A. W., Cotterill S. J., Bullimore J. A., Pearson D. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer. 1997;33(7):1061-1069.

   Not in our library10.1016/s0959-8049(97)00043-9 (opens in a new tab)

7. 7.

   Donaldson S. S., Torrey M., Link M. P., Glicksman A., Gilula L., Laurie F., Manning J., Neff J., Reinus W., Thompson E. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42(1):125-135.

   Not in our library10.1016/s0360-3016(98)00191-6 (opens in a new tab)

8. 8.

   Glasser D. B., Lane J. M., Huvos A. G., Marcove R. C., Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer. 1992;69(3):698-708.

   Not in our library10.1002/1097-0142(19920201)69:3<698::aid-cncr2820690317>3.0.co;2-g (opens in a new tab)

9. 9.

   Göbel V., Jürgens H., Etspüler G., Kemperdick H., Jungblut R. M., Stienen U., Göbel U. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987;113(2):187-191.

   Not in our library10.1007/bf00391442 (opens in a new tab)

10. 10.

    Hayes F. A., Thompson E. I., Hustu H. O., Kumar M., Coburn T., Webber B. The response of Ewing's sarcoma to sequential cyclophosphamide and adriamycin induction therapy. J Clin Oncol. 1983;1(1):45-51.

    Not in our library10.1200/jco.1983.1.1.45 (opens in a new tab)

11. 11.

    Hayes F. A., Thompson E. I., Meyer W. H., Kun L., Parham D., Rao B., Kumar M., Hancock M., Parvey L., Magill L. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol. 1989;7(2):208-213.

    Not in our library10.1200/jco.1989.7.2.208 (opens in a new tab)

12. 12.

    Hense H. W., Ahrens S., Paulussen M., Lehnert M., Jürgens H. Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI)CESS studies. Ann Oncol. 1999;10(9):1073-1077.

    Not in our library10.1023/a:1008357018737 (opens in a new tab)

13. 13.

    Huvos A. G., Rosen G., Marcove R. C. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101(1):14-18.

    Not in our library

14. 14.

    Jürgens H., Exner U., Gadner H., Harms D., Michaelis J., Sauer R., Treuner J., Voûte T., Winkelmann W., Winkler K. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer. 1988;61(1):23-32.

    Not in our library10.1002/1097-0142(19880101)61:1<23::aid-cncr2820610106>3.0.co;2-m (opens in a new tab)

15. 15.

    Kinsella T. J., Miser J. S., Waller B., Venzon D., Glatstein E., Weaver-McClure L., Horowitz M. E. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 1991;20(3):389-395.

    Not in our library10.1016/0360-3016(91)90047-8 (opens in a new tab)

16. 16.

    Mendenhall C. M., Marcus R. B., Enneking W. F., Springfield D. S., Thar T. L., Million R. R. The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer. 1983;51(5):913-917.

    Not in our library10.1002/1097-0142(19830301)51:5<913::aid-cncr2820510525>3.0.co;2-0 (opens in a new tab)

17. 17.

    Nesbit M. E., Gehan E. A., Burgert E. O., Vietti T. J., Cangir A., Tefft M., Evans R., Thomas P., Askin F. B., Kissane J. M. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990;8(10):1664-1674.

    Not in our library10.1200/jco.1990.8.10.1664 (opens in a new tab)

18. 18.

    Oberlin O., Habrand J. L., Zucker J. M., Brunat-Mentigny M., Terrier-Lacombe M. J., Dubousset J., Gentet J. C., Schmitt C., Ponvert D., Carrié C. No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10(9):1407-1412.

    Not in our library10.1200/jco.1992.10.9.1407 (opens in a new tab)

19. 19.

    Oberlin O., Patte C., Demeocq F., Lacombe M. J., Brunat-Mentigny M., Demaille M. C., Tron P., N'Guyen Bui B., Lemerle J. The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. Eur J Cancer Clin Oncol. 1985;21(4):463-467.

    Not in our library10.1016/0277-5379(85)90038-0 (opens in a new tab)

20. 20.

    Parham D. M., Hijazi Y., Steinberg S. M., Meyer W. H., Horowitz M., Tzen C. Y., Wexler L. H., Tsokos M. Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol. 1999;30(8):911-918.

    Not in our library10.1016/s0046-8177(99)90244-7 (opens in a new tab)

21. 21.
    Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples · 1977

    No notice
22. 22.

    Picci P., Rougraff B. T., Bacci G., Neff J. R., Sangiorgi L., Cazzola A., Baldini N., Ferrari S., Mercuri M., Ruggieri P. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993;11(9):1763-1769.

    Not in our library10.1200/jco.1993.11.9.1763 (opens in a new tab)

23. 23.

    Sauer R., Jürgens H., Burgers J. M., Dunst J., Hawlicek R., Michaelis J. Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol. 1987;10(2):101-110.

    Not in our library10.1016/s0167-8140(87)80052-x (opens in a new tab)

24. 24.

    Terrier P., Henry-Amar M., Triche T. J., Horowitz M. E., Terrier-Lacombe M. J., Miser J. S., Kinsella T. J., Contesso G., Llombart-Bosch A. Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis? Eur J Cancer. 1995;31A(3):307-314.

    Not in our library10.1016/0959-8049(94)00417-4 (opens in a new tab)

25. 25.

    Wilkins R. M., Pritchard D. J., Burgert E. O., Unni K. K. Ewing's sarcoma of bone. Experience with 140 patients. Cancer. 1986;58(11):2551-2555.

    Not in our library10.1002/1097-0142(19861201)58:11<2551::aid-cncr2820581132>3.0.co;2-y (opens in a new tab)

Cited by papers we hold 1

• Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives · 2021
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.